The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Videos [1486]

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally a...

Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )

Assessment of guideline adherence in breast cancer management among oncologists ...

Dr Bolanle Adegboyega - Lagos University Teaching Hospital, Lagos, Nigeria

Assessment of guideline adherence in breast cancer management among oncologists in Nigeria ( Dr Bolanle Adegboyega - Lagos University Teaching Hospital, Lagos, Nigeria )

ESMO 2021 Roundup

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

OncoAlert and ecancer - ESMO 2021 Day 5

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausa...

Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer ( Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

OncoAlert and ecancer - ESMO 2021 Day 4

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 4 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

OncoAlert and ecancer - ESMO 2021 Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer

Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Hou...

First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer ( Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Houston, Texas )

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-ne...

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trast...

Prof Nadia Harbeck - University of Munich, Munich, Germany

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in HER2/HR positive early BC ( Prof Nadia Harbeck - University of Munich, Munich, Germany )

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone recept...

Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain )

OncoAlert and ecancer - ESMO 2021 Day 2

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

More from ecancer